Halozyme Therapeutics Inc RV7.SG
€87.52 €0.98 (1.11%) 1D
Last Updated: Aug 13, 12:00 AM·XSTU
Pricing for DE stocks is delayed by 24 hours
RV7.SG Shariah Compliance
Screening Methodology: AAOIFI
As of August 2026, Halozyme Therapeutics Inc is classified as not halal.
NOT HALAL
Report Source: undefined Quarter Report
Halozyme Therapeutics Inc. Stock Analysis RV7.SG
Germany Health Care Large Cap Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company. The company is headquartered in San Diego, California and currently employs 423 full-time employees. The company went IPO on 2003-01-30. The firm's commercially-validated solution, ENHANZE drug delivery technology with the proprietary enzyme rHuPH20, is used to facilitate the subcutaneous delivery of injected drugs and fluids, with a focus on improving the patient experience with rapid subcutaneous delivery and reduced treatment burden. The firm licenses its technology to biopharmaceutical companies to collaboratively develop products that combine ENHANZE with its partners’ proprietary compounds. The company also develops, manufactures and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technologies. The firm has two commercial proprietary products, Hylenex and XYOSTED. The company also has a proprietary ultra-high concentration microparticle formulation technology for biologics, branded Hypercon.
Halozyme Therapeutics Inc (RV7.SG) Chart
Financial Metrics & Statements of Halozyme Therapeutics Inc (RV7.SG)
FAQ's for Halozyme Therapeutics Inc (RV7.SG)
- As of August 2026, Halozyme Therapeutics Inc RV7.SG is classified as not halal according to Musaffa’s Shariah screening methodology. This classification is based on an assessment of the company’s business activities and financial ratios against Islamic investment guidelines.
- A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Halozyme Therapeutics Inc using these criteria to determine its compliance status.
- Muslim investors may consider investing in Halozyme Therapeutics Inc if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
- Musaffa determines the Shariah status of Halozyme Therapeutics Inc by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
- The Shariah compliance status of Halozyme Therapeutics Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.
- Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
- You can check the latest Shariah compliance status of Halozyme Therapeutics Inc on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.
Alternate Halal Stocks for Halozyme Therapeutics Inc (RV7.SG)
Related Halal Stocks are Shariah-compliant companies that align with Islamic investment principles, avoiding prohibited industries like alcohol, gambling, and interest-based finance.
